Peptide therapy TikTok Q&A: separating hype from human data

What did @pepswithjess actually say?

Jess described a personal fat loss stack consisting of retatrutide, SLUPP332, and 5-amino-1MQ, used alongside a calorie deficit, one gram of protein per pound of bodyweight, and four to five weekly weightlifting sessions. She started retatrutide at 0.5 mg twice weekly and worked up to 2 mg total by the end of her cut. She reported zero side effects and attributed that partly to sourcing from vendors she personally knows. She also framed this as a guide for people who want to lose 40 to 50 pounds in three to four months, which is the part of this video that deserves the most scrutiny.

To her credit, she did not claim any of these compounds treat a disease, and she repeatedly told viewers to start low. But she also casually named specific doses, endorsed unregulated vendors, and implied that knowing the vendor personally is a quality assurance system. It is not.

Does the science back this up?

Retatrutide has actual clinical trial data behind it. The other two compounds in her stack largely do not, at least not in humans at this scale.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. A Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023) showed participants losing up to 24.2% of body weight over 48 weeks at the highest doses, which is genuinely impressive and among the strongest weight loss data seen in a pharmacological trial. However, that trial was conducted under rigorous medical supervision with standardized dosing protocols, not a self-directed stack from an internet vendor.

SLUPP332 is a selective PPAR-delta agonist studied in mouse models as an exercise mimetic. There are no published human clinical trials on SLUPP332 for fat loss. The foundational animal research (Narkar et al., 2008, Cell) showed metabolic benefits in mice, but translating rodent PPAR agonist data to human fat loss claims is a significant leap. 5-amino-1MQ is a small molecule NNMT inhibitor. Again, the evidence is primarily preclinical. A 2021 paper in Nature Communications (Neelakantan et al.) showed fat mass reduction in diet-induced obese mice. Human data is essentially absent.

What did they get wrong (or right)?

She got the foundational lifestyle advice right. Eating sufficient protein, maintaining a calorie deficit, and training consistently are the actual drivers of body composition change. Stating "always start very low and work your way up" is also correct harm reduction advice, regardless of what compound someone is using.

Where she went wrong is in presenting two compounds, SLUPP332 and 5-amino-1MQ, as components of a working fat loss stack when there is no human evidence to support that framing. She implies the stack worked for her because of these compounds, but that is not a controlled experiment. She was also in a calorie deficit, training five days a week, and eating high protein. Any one of those factors could account for her results entirely.

The vendor endorsement is also a problem. "I know the owners of both companies" is not a quality control standard. Without third-party certificates of analysis, independent lab testing, and pharmaceutical-grade manufacturing standards, vendor familiarity is meaningless for assessing purity or dosing accuracy of unregulated compounds.

Projecting 40 to 50 pounds of weight loss in three to four months as a realistic expectation for viewers is irresponsible. The clinical trial data on retatrutide showed those results over 48 weeks under medical supervision, not in a few months from a self-directed protocol.

What should you actually know?

If you are considering retatrutide, it is not currently FDA-approved. It is in Phase 3 trials as of 2024. Compounded versions being sold online are unregulated, and potency, purity, and sterility are not guaranteed by any independent body. This is not a reason to automatically dismiss interest, but it is a reason to involve a licensed clinician who can monitor your response, check for contraindications, and adjust dosing based on your actual labs, not a TikTok timeline.

SLUPP332 and 5-amino-1MQ are research chemicals. That description is not a scare tactic. It means the human safety profile is largely unknown, drug interactions are unstudied, and long-term effects have not been characterized. Taking them as part of a stack with other compounds compounds that uncertainty significantly.

• If fat loss is the goal, GLP-1 receptor agonist therapy through a regulated telehealth platform gives you access to compounds with actual human safety data and medical oversight.
• Vendor familiarity is not a substitute for third-party lab testing. Ask for a certificate of analysis before using any peptide from any source.
• A calorie deficit plus adequate protein plus resistance training is still doing most of the work in any fat loss outcome. Peptides can support a program. They do not replace one.